Atlas Trials

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

Clinical trial NCT04634344 · TERMINATED

Trial details

NCT number
NCT04634344
Sponsor
Dizal Pharmaceuticals
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Metastatic Castration Resistant Prostate Cancer
Start date
2021-04-12
Primary completion
2022-05-05
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.